Home  /  Resource Library  /  Inotuzumab Ozogamicin Plus R-CVP for Patients With DLBCL Who Are Ineligible for R-CHOP

Inotuzumab Ozogamicin Plus R-CVP for Patients With DLBCL Who Are Ineligible for R-CHOP

EHA 2020: Results of a phase II study investigating Inotuzumab Ozogamicin combinined with chemoimmunotherapy for first line treatment of patients with with diffuse large b-cell ineligible for R-CHOP therapy.